Business
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit
Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastom...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbb1{\nBORDER-BOTTOM:1pt\n}\n.prnsbr1{\nBORDER-RIGHT:1pt\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prntar{\nTEXT-ALIGN: RIGHT\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbt1{\nBORDER-TOP:1pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prnsbl1{\nBORDER-LEFT:1pt\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Dec. 9, 2019\n\n\n\nPresentation Will Provide Update on Survival Trends in Various Population Subgroups Medicenna to also Present at the LD Micro Investor Conference\n TORONTO and HOUSTON, Dec. 9, 2019 /CNW/ - Medicenna Therapeutics Corp.  (\"Medicenna\" or \"the Company\") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that it will present results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Glioblastoma Drug Development Annual Summit to be held on December 10 and 11 at the Westin Boston Waterfront Hotel in Boston, Massachusetts.\nThe oral presentation will provide details on survival seen in patients with rGBM from the MDNA55 Phase 2b clinical trial, including trends observed in different population subgroups.\nThe details of the presentation are as follows:\nTitle:            \nClinical Case Study: Using a Multi-pronged Approach to Treating Recurrent GBM             \n- Overcoming the Tumor and its Microenvironment\nPresenter:    \nDr. Fahar Merchant, PhD, President and CEO of Medicenna Therapeutics\nDate/Time:   \nWednesday, December 11, 2019 at...